🇺🇸 FDA
Pipeline program

VCA-894A

VP-VCA-894A-2101

Phase 2 small_molecule active

Quick answer

VCA-894A for Charcot Marie Tooth Disease (CMT) is a Phase 2 program (small_molecule) at Vanda Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Vanda Pharmaceuticals
Indication
Charcot Marie Tooth Disease (CMT)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials